Proactive Investors - Run By Investors For Investors

Genetic Technologies sees increase in breast cancer test numbers

Genetic Technologies sees increase in breast cancer test numbers

Genetic Technologies (ASX:GTG, NASDAQ:GENE) has increased the number of BREVAGen breast cancer test samples returned in the June 2014 quarter by 37% over the March 2014 quarter.
This represents a return to levels achieved in late 2013.

It also brings the total samples received to 3,935 for the 2014 financial year, more than double the 1,547 received in the previous corresponding period.

The company is also on target to release the next generation BREVAGen test in the fourth quarter of this year.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

View full GTG profile View Profile

Genetic Technologies Timeline

March 06 2015

Related Articles

November 19 2018
“It’s a blended model of highly cash generative assets and top line growth”
researcher filling a tray of samples
December 14 2018
The company has two clinical trials underway and is well funded to achieve its immediate ambitions
January 03 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use